Global Media Strategies -- Your Brand, Your Audience

BEMA Buprenorphine Phase 2 Study Results Selected for Presentation at Pain Week 2010

August 31, 2010 By: NCTechNews Category: Pharmaceuticals

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

BDSI previously announced positive top-line results from the study which showed that BEMA Buprenorphine demonstrated a statistically significant improvement compared to placebo in the primary efficacy endpoint, SPID-8 (sum of pain intensity differences at 8 hours; baseline observation carried forward analysis).

In addition, data will be presented which looked at a subset of patients with severe pain, where the analgesic efficacy of BEMA Buprenorphine was more profound.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the Company’s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009 for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda AB, who launched ONSOLIS in the U.S. last October, and Kunwha Pharmaceutical Co. Ltd. BDSI’s second pain product, BEMA Buprenorphine, completed Phase 2 clinical development for the treatment of pain; a higher dose formulation is being developed for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). BDSI’s headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.

Comments are closed.

← North Carolina Home Medical Equipment Companies Attend CMS Training Session in Charlotte
BioDelivery Sciences Adds New Executive to Lead Business and Strategic Development →

  • Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

    Video: QC in Pharma Mfg


    Defense Industry Gets More Competitive
    U.S. troop level decreases and shrinking armed forces budgets will lead to increased competition and a change in business operations for military contractors in North Carolina and throughout the nation, according to defense industry contracting expert Lea Strickland, requiring a more strategic and tactical approach to developing professional, properly-designed bid proposals.

    A Leg Up for Students
    Innovative concept-to-marketplace product design and development firm Montie Design is holding a Winter 2012 Student Design Contest for aspiring product designers in community colleges, four-year colleges, or high schools from North Carolina and Virginia, starting February 1.

    getting from lab 2 line
    The leader in analytical instrumentation for the pharma manufacturing industry has named a new COO responsible for manufacturing, engineering, software development, and project management for hardware and software products such as the VTT-1000 multi-variant testing device, breaking down barriers to speeding-up the drug manufacturing pipeline and cutting-down on drug shortages.

  • Recent Headlines

















free web site traffic and promotion